[{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hackensack Meridian Health \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||PML-RAR-alpha||Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||PML-RAR-alpha||Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||PML-RAR-alpha||Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||PML-RAR-alpha||Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||PML-RAR-alpha||Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aphios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"||PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aphios \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aphios \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Medical Research Council | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Queen Mary University of London \/ Medical Research Council | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Queen Mary University of London \/ Medical Research Council | Bristol Myers Squibb"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UT Southwestern Medical Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Genentech"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Beimei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Beimei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Beimei Pharma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"MagnaPharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ MagnaPharm","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ MagnaPharm"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"SEARCHLIGHT PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ SEARCHLIGHT PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ SEARCHLIGHT PHARMA"},{"orgOrder":0,"company":"GALDERMA LABS LP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"GALDERMA LABS LP","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"GALDERMA LABS LP \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GALDERMA LABS LP \/ Inapplicable"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Ortho Dermatologics","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Ortho Dermatologics"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"M. Arkin Dermatology Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Benzoyl Peroxide","moa":"||Keratinocyte","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd"},{"orgOrder":0,"company":"Stephen Bagley, MD, MSCE","sponsor":"Incyte Corporation | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"All-Trans Retinoic Acid","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Stephen Bagley, MD, MSCE","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stephen Bagley, MD, MSCE \/ Incyte Corporation | University of Pennsylvania","highestDevelopmentStatusID":"8","companyTruncated":"Stephen Bagley, MD, MSCE \/ Incyte Corporation | University of Pennsylvania"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||RAR-beta\/gamma","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Carrick Therapeutics \/ Arvinas","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Arvinas"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Shanghai Longfine Biotechnology Co., Ltd. | TopAlliance","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Shanghai Longfine Biotechnology Co., Ltd. | TopAlliance","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Shanghai Longfine Biotechnology Co., Ltd. | TopAlliance"}]

Find Clinical Drug Pipeline Developments & Deals for Tretinoin 0.1% cream or placebo

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : HF1K16 (ATRA liposome) is a novel small molecule RARβ2 agonist which is being evaluated for variety of refractory metastatic solid tumors such as gliomas, colorectal, liver, lung and ovarian cancers.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 16, 2024

                          Lead Product(s) : Tretinoin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : HF1K16 (ATRA liposome) is a small molecule RARβ2 agonist, evaluated in Phase 1 trials for various refractory metastatic solid tumors including gliomas, stomach, colorectal, liver, and lung cancers.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : Tretinoin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The agreement aims for the commercialization of Twyneo (tretinoin/benzoyl peroxide) and Epsolay (benzoyl peroxide) covering the majority of the European countries.

                          Product Name : Twyneo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 25, 2024

                          Lead Product(s) : Tretinoin,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : MagnaPharm

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Beimei purchases and licenses rights to exclusively commercialize Twyneo (tretinoin). It is an approved product indicated for acne vulgaris in adults and pediatric patients 9 years of age and older.

                          Product Name : Twyneo

                          Product Type : Other Small Molecule

                          Upfront Cash : $10.0 million

                          May 16, 2024

                          Lead Product(s) : Tretinoin,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Beimei Pharma

                          Deal Size : $15.0 million

                          Deal Type : Agreement

                          blank

                          05

                          First Affiliated Hospital of Zhejiang University

                          Country arrow
                          EPSC
                          Not Confirmed

                          First Affiliated Hospital of Zhejiang University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 17, 2024

                          Lead Product(s) : Tretinoin,Toripalimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Shanghai Longfine Biotechnology Co., Ltd. | TopAlliance

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris.

                          Product Name : Twyneo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 06, 2024

                          Lead Product(s) : Tretinoin,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Apotex Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist combined with Benzoyl Peroxide for treating acne vulgaris in patients aged 9 and older.

                          Product Name : Twyneo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 04, 2024

                          Lead Product(s) : Tretinoin,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Apotex Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A. It is administered by infusion, travels through the blood stream and infiltrates the tumor microenvironment.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 23, 2023

                          Lead Product(s) : Tretinoin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 21, 2023

                          Lead Product(s) : Tretinoin,Atezolizumab,Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A, administered by infusion, it travels through the blood stream and infiltrates the tumor microenvironment. ATRA is released and initiate maturation of myeloid-derived...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 17, 2023

                          Lead Product(s) : Tretinoin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank